Recent Advances in Dopamine Receptor Ligands as Chemical Biology Tools.

Michael Dorogan, Hari K Namballa, Sandip Patra, Wayne W Harding

Abstract readReview

In one paragraph

Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael DoroganDepartment of Chemistry, University of Pittsburgh, Chevron Science Center, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260, United States.ORCID https://orcid.org/0000-0001-9431-2539

Hari K NamballaDepartment of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-1417-7937

Sandip PatraDepartment of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-9679-3580

Wayne W HardingDepartment of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, New York 10065, United States.ORCID https://orcid.org/0000-0002-1866-3553

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dopamine receptors (DRs) have been implicated in numerous disorders and diseases (e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, and substance use disorders) and have served as attractive drug targets for these ailments. Despite their potential clinical utility, the development of selective DR ligands has been challenging due to difficulties in selectivity among the DR subtypes as well as other biogenic amine receptors and poor pharmacokinetic properties. The realization of their full potential necessitates continued advancements in DR ligands as investigative tools. This review aims to highlight the recent developments made in the chemical biology of DR ligands (e.g., bivalent ligands, photoactivatable ligands, photoswitchable probes, and fluorescent probes).

Identifiers

PMID42368109

DOI10.1021/acsomega.6c01474

PMCPMC13295018

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.